

Screening Tool Guides Need for Islet Antibody Test

BY MARY ANN MOON
Contributing Writer

A relatively simple screening tool helps determine whether patients who present with adult-onset diabetes have type 2 disease or latent autoimmune diabetes, according to Dr. Spiros Furlanos and his associates at the Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria (Australia).

Latent autoimmune diabetes, which is

believed to signal slowly progressive autoimmune β -cell destruction, is a form of type 1 disease characterized by adult onset; circulating islet cell antibodies and glutamic acid decarboxylase antibodies; and no initial need for insulin therapy. However, patients often have dramatic loss of β -cell function within 3 years of diagnosis, which quickly leads to insulin dependence.

"We believe that physicians need to be aware that patients with [latent autoimmune diabetes] are prone to insulin defi-

ciency and often require rapid escalation of oral hypoglycemic treatment or commencement of insulin earlier than islet antibody-negative patients," Dr. Furlanos and his associates said (*Diabetes Care* 2006;29:970-5).

Despite the frequency of the disorder and the difficulty in distinguishing it from type 2 diabetes, "there are no universal recommendations regarding testing for islet antibodies in adult-onset diabetes. Currently, many physicians test for islet anti-

bodies only if they suspect [latent autoimmune diabetes]," the researchers said. Since most physicians also assume that this disorder affects only normal-weight individuals, overweight adults who are diagnosed as having diabetes are presumed to have type 2 disease and are not tested.

The investigators conducted a retrospective study of 102 patients with latent autoimmune diabetes and 111 with type 2 diabetes to determine which clinical features distinguished the two groups so that they could develop a simple screening tool for physicians in clinical practice.

The subjects with latent autoimmune diabetes were significantly younger at diagnosis (median age 46 years vs. 61 years). Most (67%) had acute symptoms, such as polydipsia, polyuria, or unintentional weight loss, whereas only a minority of patients with type 2 diabetes (28%) were symptomatic. The median body mass index (BMI) was lower in the subjects with latent autoimmune diabetes, but a major-

Onset after age 50, BMI over 25, acute symptoms, and a history of autoimmune disease were associated with a high risk of latent autoimmune diabetes.

ity of them still qualified as overweight or obese. Finally, most also had a personal or family history of autoimmune disease, whereas subjects with type 2 diabetes did not.

Dr. Furlanos and his associates used these five clinical traits to fashion a screening tool, and validated its usefulness in a prospective study of 130 subjects aged 30-75 years with recently diagnosed diabetes who didn't require insulin therapy. Subjects who had at least two of the five clinical features—age of onset older than 50, acute symptoms, BMI (kg/m^2) greater than 25, personal history of autoimmune disease, or family history of autoimmune disease—were more likely to have latent autoimmune diabetes and warranted antibody testing.

If these patients are not tested and identified, "our experience is that suboptimal glycemia in such patients is frequently prolonged because it is not attributed to autoimmune diabetes and insulin deficiency," they noted.

The screening also proved highly reliable at excluding a diagnosis of latent autoimmune diabetes in patients who had none or one of these features, with a negative predictive value of 99%. A score of 0 or 1 on this screen will exclude the autoimmune disorder and thus the need for antibody testing in approximately two-thirds of adults with diabetes, they added.

"This clinical screening method is superior to the current popular clinical practice of only screening patients with [a low] BMI ... because a majority of subjects with [latent autoimmune diabetes] are overweight or obese," the investigators said.

Use of this screening tool should increase the identification of autoimmune diabetes and improve clinical management, they said. ■

Register Today at:
www.womenshealthcongress.com
 or call 888-799-2995




WOMEN'S HEALTH CONGRESS


November 10-12, 2006 • The Palace Hotel, San Francisco

Presented by: *Ob.Gyn. News* *Family Practice News* *Clinical Psychiatry News* *Internal Medicine News*

Program Chair:
Anita L. Nelson, MD
David Geffen School of Medicine
at UCLA /UCLA Medical Center

Co-Chairs:
Sidney Goldstein, MD
Case Western Reserve University
School of Medicine /
Henry Ford Hospital
Paul S. Jellinger, MD, MACE
University of Miami

Charles E. Miller, MD, FACOG
University of Illinois at Chicago /
University of Chicago
E. Albert Reece, MD, PhD, MBA
University of Arkansas College of
Medicine



Improving the Care of Your Female Patient

This educational conference focuses on the conditions and diseases that may be unique to women, are more prevalent in women, or manifest different in women. A multidisciplinary faculty addresses prevention, symptoms, diagnosis, and treatment strategies with emphasis on the complete and unique needs of the female patient.



Clinical Highlights:

- ADHD in Women
- Depression & Anxiety
- Management of Insomnia
- Type II Diabetes
- Bipolar Illness
- Hyperactive Bladder/Incontinence
- Smoking Cessation
- Women's Sexuality
- Cancer Screening
- Hypertension & Stroke
- STIs and Abnormal Pap
- Contraception Update
- Infertility Update
- The Obesity Epidemic
- Treating Chronic Pain



The Women's Health Congress is jointly sponsored by the Elsevier Office of Continuing Medical Education and Elsevier/International Medical News Group.

